Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adg138
- Development stage
- Discontinued
- Lead developer
- Adagene
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ADG138 is a novel bispecific T-cell engager (TCE) antibody designed to target both HER2 (ERBB2) and CD3. It integrates precision masking technology to control cytokine release syndrome and on-target off-tumor toxicity. The drug is intended for use as a single agent or in combination with other immune modulating agents for the treatment of HER2-expressing solid tumors. Preclinical data have shown potent anti-tumor activity in both high and low HER2-expressing tumors, including resistant/refractory tumors, with an excellent safety profile—demonstrating a 100-fold reduction in cytokine release compared to its parental non-masked TCE[1][4][6].
- Other names
- HER2xCD3 POWERbodyHER-2xCD3 POWERbodyHER 2xCD3 POWERbodyPOWERbodySAFEbody engineered T cell engager targeting HER2
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)CD3D (T-cell surface glycoprotein CD3 delta chain)
Beyond the preview
Go deeper on adg138.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adg138.